文献速递肿瘤 PET/CT甲状腺核医学

同步全身18F-PSMA-1007-PET/MRI联合前列腺窝高分辨率多参数成像用于前列腺癌患者全面肿瘤分期的初步研究

Simultaneous whole-body 18F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-10-16

本研究纳入8例高危活检证实的前列腺癌患者,其中7例未治疗、1例生化复发,在18F-PSMA-1007-PET/CT(注射后1小时)作为参考后行全身PET/MRI(注射后3小时)并包含多参数前列腺MRI。结果显示PET/CT与PET/MRI的SUVmean显著相关(p<0.0001),PET与MRI可互补检测T2c至T4特征,同步PET读取实现最佳配准。

要点

  • 7例未治疗和1例生化复发前列腺癌患者接受全身18F-PSMA-1007-PET/MRI及多参数前列腺MRI。
  • PET/CT(1小时)与PET/MRI(3小时)的SUVmean值显著相关(p<0.0001)。
  • PET/MRI在肝脏和肾脏周围显示中度光子缺失PET伪影,PET/CT未见PET伪影。

核心结论

  • 所提出的18F-PSMA-1007-PET/MRI协议将高效全身评估与前列腺窝高分辨率配准PET/MRI相结合,用于前列腺癌患者的全面肿瘤分期。

研究设计与样本

  • 初步研究,8例高危活检证实的前列腺癌患者接受全身PET/MRI(注射后3小时)包括多参数前列腺MRI,此前以18F-PSMA-1007-PET/CT(注射后1小时)作为参考。
  • 7例患者为未治疗前列腺癌,1例为生化复发。
  • 使用3D等轮廓感兴趣体积进行SUVmean定量,影像数据用于TNM分期并与组织病理学比较,其中4/7例患者术后经组织病理学确认前列腺癌。
  • 评估PET伪影、盆腔PET/MRI与MRI数据的配准(PI-RADS 2.0)。

主要发现

  • 检查被患者良好接受,耗时1小时。
  • PET/CT(注射后1小时)与PET/MRI(注射后3小时)之间的SUVmean值显著相关(p<0.0001),与18F-PSMA-1007-PET/CT注射后1小时 vs 3小时的文献相似。
  • 在全部7例患者中,PET和MRI均能检测到主导性前列腺内病灶。
  • 在5例患者中,PET和MRI互补检测到T2c、T3a、T3b和T4特征。
  • PET/MRI显示肝脏和肾脏周围中度光子缺失PET伪影,代表高对比度区域,PET/CT未见PET伪影;前列腺MRI同步PET读取实现最佳配准结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The aim of the present study was to explore the clinical feasibility and reproducibility of a comprehensive whole-body 18F-PSMA-1007-PET/MRI protocol for imaging prostate cancer (PC) patients. METHODS: Eight patients with high-risk biopsy-proven PC underwent a whole-body PET/MRI (3 h p.i.) including a multi-parametric prostate MRI after 18F-PSMA-1007-PET/CT (1 h p.i.) which served as reference. Seven patients presented with non-treated PC, whereas one patient presented with biochemical recurrence. SUVmean-quantification was performed using a 3D-isocontour volume-of-interest. Imaging data was consulted for TNM-staging and compared with histopathology. PC was confirmed in 4/7 patients additionally by histopathology after surgery. PET-artifacts, co-registration of pelvic PET/MRI and MRI-data were assessed (PI-RADS 2.0). RESULTS: The examinations were well accepted by patients and comprised 1 h. SUVmean-values between PET/CT (1 h p.i.) and PET/MRI (3 h p.i.) were significantly correlated (p < 0.0001, respectively) and similar to literature of 18F-PSMA-1007-PET/CT 1 h vs 3 h p.i. The dominant intraprostatic lesion could be detected in all seven patients in both PET and MRI. T2c, T3a, T3b and T4 features were detected complimentarily by PET and MRI in five patients. PET/MRI demonstrated moderate photopenic PET-artifacts surrounding liver and kidneys representing high-contrast areas, no PET-artifacts were observed for PET/CT. Simultaneous PET-readout during prostate MRI achieved optimal co-registration results. CONCLUSIONS: The presented 18F-PSMA-1007-PET/MRI protocol combines efficient whole-body assessment with high-resolution co-registered PET/MRI of the prostatic fossa for comprehensive oncological staging of patients with PC.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Freitag MT, Kesch C, Cardinale J, et al. Simultaneous whole-body 18F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2017. PMID: 29038888. doi:10.1007/s00259-017-3854-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。